Certolizumab pegol

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Certolizumab pegol
Accession Number
DB08904
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb) / Fusion proteins
Description

Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha).1 It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life.3

Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as E. coli.3 It was developed and manufactured by UCB Pharma, first FDA approved in 200811 and updated for a new indication on March 28, 2019.10

Protein structure
Db08904
Protein chemical formula
C2115H3252N556O673S16
Protein average weight
91000.0 Da (Pegylated)
Sequences
>Amino acid sequence of the light chain
DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPY
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>Amino acid sequence of the heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIY
ADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCAA
References:
  1. Lee JU, Shin W, Son JY, Yoo KY, Heo YS: Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. Int J Mol Sci. 2017 Jan 23;18(1). pii: ijms18010228. doi: 10.3390/ijms18010228. [PubMed:28124979]
  2. Patents [Link]
Download FASTA Format
Synonyms
  • Certolizumab pegol
External IDs
CDP 870 / CDP-870 / CDP870 / PHA-738144
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CimziaInjection, solution200 mgSubcutaneousUcb Pharma Sa2009-10-01Not applicableEu
CimziaInjection, solution200 mg/1mLSubcutaneousUCB, Inc.2009-05-14Not applicableUs
CimziaInjection, solution200 mgSubcutaneousUcb Pharma Sa2009-10-01Not applicableEu
CimziaKit200 mg/1mLUCB, Inc.2008-04-20Not applicableUs
CimziaInjection, solution200 mgSubcutaneousUcb Pharma Sa2009-10-01Not applicableEu
CimziaSolution200 mgSubcutaneousUcb Inc2017-08-04Not applicableCanada
CimziaInjection, solution200 mgSubcutaneousUcb Pharma Sa2009-10-01Not applicableEu
CimziaSolution200 mgSubcutaneousUcb Inc2009-08-31Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
UMD07X179E
CAS number
428863-50-7

Pharmacology

Indication

Certolizumab pegol has been approved for several different conditions listed below:

  • Symptomatic management of Chron's disease patients and for the maintenance of clinical response in patients with moderate to severe disease with inadequate response to conventional therapy.
  • Treatment of adult patients with moderate to severely active rheumatoid arthritis.
  • Treatment of adult patients with active psoriatic arthritis.
  • Treatment of adult patients with active ankylosing spondylitis.
  • Treatment of adult patients with moderate-to-severe plaque psoriasis that are candidates for systemic therapy or phototherapy.Label
  • Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation.10

In Canada, certolizumab pegol is additionally approved in combination with methotrexate for the symptomatic treatment, including major clinical response, and for the reduction of joint damage in adult patients with moderately to severely active rheumatoid arthritis and psoriatic arthritis.12

Inflammation is a biological response against a potential threat. This response can be normal but in certain conditions, the immune system can attack the body's normal cells or tissues which causes an abnormal inflammation.13 TNF-alpha has been identified as a key regulator of the inflammatory response. The signaling cascades of this inflammatory mediator can produce a wide range of reactions including cell death, survival, differentiation, proliferation and migration.7

Associated Conditions
Pharmacodynamics

As part of the mechanism of action and nature of the drug, certolizumab does not induce apoptosis in cultured lymphocytes and monocytes. However, as a piece of the inhibition of inflammation, certolizumab pegol inhibits lipopolysaccharide-induced production of IL-1 beta and it induces nonapoptotic cell death via signaling transmembrane TNF-alpha.3

In vitro studies with certolizumab pegol in human tissue did not show any unexpected binding at 3 mcg/ml nor at 10 mcg/ml. Due to the drug class, certolizumab pegol is not expected to present adverse effects on the major vital systems.14

In phase III clinical trials in psoriatic arthritis patients, certolizumab pegol was reported to generate improvements in skin disease, joint involvement, dactylitis, enthesitis and general life quality. The clinical effect of certolizumab was paired to a comparable safety profile to other TNF-alpha inhibitors.3

The clinical effectiveness of certolizumab pegol was mainly studied in six randomized controlled trials that compared its effect versus placebo. In a comparative study, the efficacy for certolizumab pegol registered ranged from 30-65% while in placebo ranged from 4-25%.5 However, in other additional trials, certolizumab was proven to present a similar clinical efficacy to other disease-modifying antirheumatic drugs in patients with inadequate response to TNF inhibitors.2

Mechanism of action

Certolizumab targets the activation of TNF-alpha with high affinity (KD 90 pM and IC90 0.004 mcg/ml) which in order, inhibits the downstream inflammatory process.1 It acts by binding and neutralizing the soluble and membrane portions of TNF-alpha without inducing complement or antibody-dependent cytotoxicity due to the lack of the Fc region. The inhibition of TNF-alpha is achieved in a dose-dependent manner and it does not present activity against lymphotoxin alpha (TNF-beta).3,14

One additional feature od certolizumab pegol is that, due to the presence of the PEGylation, it is more significantly distributed into inflamed tissues when compared to other TNF-alpha inhibitors such as infliximab and adalimumab.3

TargetActionsOrganism
ATumor necrosis factor
neutralizer
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

After subcutaneous administration, the peak plasma concentration is reached between 54 and 171 hours with a bioavailability of 80%.3 Certolizumab presents a linear pharmacokinetic profile with a peak plasma concentration of 43-49 mcg/ml.14

Volume of distribution

Certolizumab pegol volume of distribution is reported to be in the range of 4-8 L.8 It is known to have a very good distribution in the joints when compared to other TNF-alpha inhibitors.6

Protein binding

Monoclonal antibodies are usually not required to have protein binding studies.

Metabolism

The presence of PEG group in certolizumab pegol delays the metabolism and elimination of this drug. However, once under metabolism, the PEG group gets cleaved from the parent compound and the antibody section is thought to be internalized cells and rescued from metabolism by recycling. Later, it is degraded in the reticuloendothelial system to small peptides and amino acids which can be used for de-novo protein synthesis.4 On the other hand, the PEG section is processed normally by the action of the alcohol dehydrogenase to the formation of carboxylic acid.9

Route of elimination

As certolizumab is a monoclonal antibody, the elimination route is not widely studied. However, it is known that the elimination of the PEG moiety is dependent on the renal function which links it directly with a high portion of renal elimination.3

Half life

The circulatory half-life of certolizumab is of 14 days.3

Clearance

The clearance rate of certolizumab pegol ranged between 9-14 ml/h when administered intravenously. However, when administered subcutaneously, the clearance rate is estimated to range between 14-21 ml/h depending on the patient condition.14

Toxicity

The oral ld50 observed in mice is determined to be of 300 mg/kg.MSDS To this date, there have not been reports of overdosage, however, in case of accidental overexposure close monitoring is recommended.Label

Certolizumab pegol does not present mutagenic potential nor presents effects in fertility and reproductive performance. On the other hand, carcinogenicity studies have not been performed.Label

Affected organisms
  • Humans
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with Certolizumab pegol.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with Certolizumab pegol.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Certolizumab pegol.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be increased when combined with Certolizumab pegol.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be increased when combined with Certolizumab pegol.
5-androstenedioneThe metabolism of 5-androstenedione can be increased when combined with Certolizumab pegol.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be increased when combined with Certolizumab pegol.
7-ethyl-10-hydroxycamptothecinThe metabolism of 7-ethyl-10-hydroxycamptothecin can be increased when combined with Certolizumab pegol.
8-azaguanineThe metabolism of 8-azaguanine can be increased when combined with Certolizumab pegol.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be increased when combined with Certolizumab pegol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Evidence Level

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L: Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess. 2017 Oct;21(56):1-326. doi: 10.3310/hta21560. [PubMed:28976302]
  2. Bermejo I, Stevenson M, Archer R, Stevens JW, Goka E, Clowes M, Scott DL, Young A: Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-alpha Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2017 Nov;35(11):1141-1151. doi: 10.1007/s40273-017-0521-5. [PubMed:28550592]
  3. Acosta-Felquer ML, Rosa J, Soriano ER: An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatol. 2016 Mar 30;8:37-44. doi: 10.2147/OARRR.S56837. eCollection 2016. [PubMed:27843368]
  4. Tabrizi MA, Tseng CM, Roskos LK: Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006 Jan;11(1-2):81-8. doi: 10.1016/S1359-6446(05)03638-X. [PubMed:16478695]
  5. D'Angelo S, Tramontano G, Gilio M, Leccese P, Olivieri I: Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol. 2017 Mar 2;9:21-28. doi: 10.2147/OARRR.S56073. eCollection 2017. [PubMed:28280401]
  6. Lee JU, Shin W, Son JY, Yoo KY, Heo YS: Molecular Basis for the Neutralization of Tumor Necrosis Factor alpha by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. Int J Mol Sci. 2017 Jan 23;18(1). pii: ijms18010228. doi: 10.3390/ijms18010228. [PubMed:28124979]
  7. Bradley JR: TNF-mediated inflammatory disease. J Pathol. 2008 Jan;214(2):149-60. doi: 10.1002/path.2287. [PubMed:18161752]
  8. Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ: Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet. 2017 Dec;56(12):1513-1523. doi: 10.1007/s40262-017-0535-3. [PubMed:28353055]
  9. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D: PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2007 Jan;35(1):9-16. doi: 10.1124/dmd.106.012419. Epub 2006 Oct 4. [PubMed:17020954]
  10. FDA news [Link]
  11. FDA approvals [Link]
  12. Pubmed books [Link]
  13. Nature [Link]
  14. CIMZIA (Certolizumab) Australian Report [File]
External Links
KEGG Drug
D03441
PubChem Substance
347910385
ChEMBL
CHEMBL1201831
PharmGKB
PA165107055
Wikipedia
Certolizumab_pegol
ATC Codes
L04AB05 — Certolizumab pegol
AHFS Codes
  • 92:36.00 — Disease-modifying Antirheumatic Agents
  • 56:92.00 — Miscellaneous GI Drugs
FDA label
Download (1.71 MB)
MSDS
Download (479 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdenocarcinoma of Lung Stage IV1
1CompletedNot AvailableSperm Quality1
1CompletedBasic ScienceBioavailability Study on Healthy Volunteers1
1CompletedOtherAnkylosing Spondylitis (AS) / Axial Spondyloarthritis (AxSpA) / Crohn's Disease (CD) / Non-radiographic Evidence-AxSpA / Psoriatic Arthritis / Rheumatoid Arthritis2
1CompletedTreatmentHealthy Volunteers2
2Active Not RecruitingTreatmentAnkylosing Spondylitis (AS)1
2Active Not RecruitingTreatmentUlcerative Colitis (UC)1
2CompletedTreatmentChronic Plaque Psoriasis1
2CompletedTreatmentCrohn's Disease (CD)4
2CompletedTreatmentPsoriasis1
2CompletedTreatmentRheumatoid Arthritis2
2RecruitingPreventionAntiphospholipid Syndrome in Pregnancy / Complications, Pregnancy / High Risk Pregnancies / Lupus Anticoagulant Disorder1
2TerminatedTreatmentCrohn's Disease (CD)1
2, 3CompletedTreatmentGeneralized Pustular Psoriasis and Erythrodermic Psoriasis / Psoriasis, Moderate to Severe1
2, 3CompletedTreatmentRheumatoid Arthritis1
3Active Not RecruitingTreatmentAnkylosing Spondylitis (AS) / Axial Spondyloarthrithis1
3Active Not RecruitingTreatmentNonradiographic Axial Spondyloarthritis / Nr-axSpA / Spondyloarthritis, Axial1
3Active Not RecruitingTreatmentPolyarticular-course Juvenile Idiopathic Arthritis (JIA)1
3Active Not RecruitingTreatmentRheumatoid Arthritis1
3CompletedNot AvailableCrohn's Disease (CD)2
3CompletedBasic ScienceRheumatoid Arthritis1
3CompletedTreatmentActive Rheumatoid Arthritis1
3CompletedTreatmentCrohn's Disease (CD)8
3CompletedTreatmentInterstitial Cystitis1
3CompletedTreatmentActive Ankylosing spondylitis / Moderate and Severe Active Rheumatoid Arthritis / Moderately to Severely Active Crohn's Disease / Psoriatic arthritis aggravated1
3CompletedTreatmentPsoriasis / Psoriasis Vulgaris (Plaque Psoriasis)3
3CompletedTreatmentPsoriatic Arthritis1
3CompletedTreatmentRheumatoid Arthritis21
3CompletedTreatmentSpondyloarthropathies1
3RecruitingTreatmentRheumatoid Arthritis1
3TerminatedTreatmentCrohn's Disease (CD)2
3TerminatedTreatmentRheumatoid Arthritis1
3Unknown StatusTreatmentCrohn's Disease (CD)1
3WithdrawnTreatmentCrohn's Disease (CD)2
4Active Not RecruitingTreatmentAnterior Uveitis (AU) / Axial Spondyloarthritis (AxSpA)1
4Active Not RecruitingTreatmentRheumatoid Arthritis1
4CompletedNot AvailableRheumatoid Arthritis1
4CompletedBasic ScienceRheumatoid Arthritis1
4CompletedTreatmentRheumatoid Arthritis7
4Not Yet RecruitingTreatmentCrohn's Disease (CD)1
4RecruitingBasic ScienceRheumatoid Arthritis1
4RecruitingTreatmentRheumatoid Arthritis4
4TerminatedNot AvailableCrohns Disease1
4TerminatedTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentAnkylosing Spondylitis (AS) / High Blood Pressure (Hypertension) / Psoriatic Arthritis / Rheumatoid Arthritis1
4Unknown StatusTreatmentCrohn's Disease (CD)1
Not AvailableActive Not RecruitingNot AvailableCrohn's Disease (CD)1
Not AvailableActive Not RecruitingNot AvailableCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD)1
Not AvailableAvailableNot AvailableCrohn's Disease (CD)1
Not AvailableAvailableNot AvailableRheumatoid Arthritis1
Not AvailableCompletedNot AvailablePsoriatic Arthritis / Rheumatoid Arthritis / Spondyloarthritis1
Not AvailableCompletedNot AvailableRheumatoid Arthritis1
Not AvailableCompletedTreatmentCrohn's Disease (CD)1
Not AvailableRecruitingNot AvailableEnthesitis / Psoriasis / Psoriatic Arthritis1
Not AvailableRecruitingNot AvailableRheumatoid Arthritis2
Not AvailableRecruitingPreventionCardiovascular Disease (CVD) / Rheumatoid Arthritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionSubcutaneous200 mg/1mL
Injection, solutionSubcutaneous200 mg
Kit200 mg/1mL
SolutionSubcutaneous200 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2380298No2010-09-282021-06-05Canada
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)61ºCVermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
boiling point (°C)Fab domain denaturates at 60 ºC Arnoldus W. et al. (2000). Biophysical Journal. Vol 78. 394-404
water solubilitySolublePasut G. 2014. BioDrugs.
isoelectric point6.6 - 7.2Jin, et al. Electrophoresis. Sep;23(19):3385-91. (2002).

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Neutralizer
General Function
Tumor necrosis factor receptor binding
Specific Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac...
Gene Name
TNF
Uniprot ID
P01375
Uniprot Name
Tumor necrosis factor
Molecular Weight
25644.15 Da
References
  1. Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R: Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013 Apr 15;7:339-48. doi: 10.2147/DDDT.S31658. Print 2013. [PubMed:23620660]
  2. Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L: Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess. 2017 Oct;21(56):1-326. doi: 10.3310/hta21560. [PubMed:28976302]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
L-glucuronate reductase activity
Specific Function
Catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic aldehydes to their corresponding alcohols. Catalyzes the reduction of mevaldate to mevalonic acid and of glyceraldehyd...
Gene Name
AKR1A1
Uniprot ID
P14550
Uniprot Name
Alcohol dehydrogenase [NADP(+)]
Molecular Weight
36572.71 Da
References
  1. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D: PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos. 2007 Jan;35(1):9-16. doi: 10.1124/dmd.106.012419. Epub 2006 Oct 4. [PubMed:17020954]

Drug created on June 11, 2013 00:11 / Updated on May 21, 2019 12:23